News
Press Releases
2020/03/11
WuXi AppTec Wuhan Site Resumes Operation
SHANGHAI, March 11, 2020 – WuXi AppTec announced today that the company’s Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines. Operations at the Wuhan facility, which provides discovery chemistry services, will ramp up over the coming days and weeks. With this site’s re-opening, WuXi AppTec has now resumed operations at all facilities in China. WuXi AppTec is taking every precaution to ensure the health and safety of its employees across every site.
Read more2020/02/12
WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday
SHANGHAI, February 12, 2020 - With the end of the extended Lunar New Year holiday, WuXi AppTec sites in China have resumed operations today, with the exception of our site in Wuhan, which will reopen when local regulations permit. These steps are being taken in compliance with disease control guidelines pertaining to the coronavirus outbreak and with the utmost attention to the health and safety of our employees and their families.
Read more2020/01/13
WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform
January 13, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.
Read more2020/01/03
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
Shanghai, January 3, 2020: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China. This significant milestone marks WuXi STA’s establishment of a comprehensive one-stop platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial. It enables customers around the world to advance promising new oligonucleotide therapies more rapidly to market for the benefit of patients.
Read more2019/11/29
WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products
Shanghai and Seoul, November 29, 2019 - WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus products. Under the terms of the collaboration, WuXi ATU will provide overall process development, manufacturing and Investigational New Drug (IND) filing services for GeneMedicine’s oncolytic virus products.
Read more